{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:54:59Z","timestamp":1770746099404,"version":"3.49.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":1419,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"crossref","award":["NOI-AI-15436"],"award-info":[{"award-number":["NOI-AI-15436"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"crossref","award":["25XS065"],"award-info":[{"award-number":["25XS065"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.virol.2010.10.021","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T04:21:03Z","timestamp":1289449263000},"page":"328-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy"],"prefix":"10.1016","volume":"409","author":[{"given":"Nanhai","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford J.","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Schriewer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gelita","family":"Owens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torgny","family":"Fredrickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Mark L.","family":"Buller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2010.10.021_bb0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.gt.3300550","article-title":"Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins","volume":"5","author":"Andreansky","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2010.10.021_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/1043-4666(92)90068-3","article-title":"Biological effects of recombinant vaccinia virus-expressed interleukin 4","volume":"4","author":"Andrew","year":"1992","journal-title":"Cytokine"},{"key":"10.1016\/j.virol.2010.10.021_bb0015","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/JVI.72.5.4080-4087.1998","volume":"72","author":"Bembridge","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-4615-5357-1_49","article-title":"IL-4 gene transfer for the treatment of experimental gliomas","volume":"451","author":"Benedetti","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.virol.2010.10.021_bb0025","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1073\/pnas.82.7.2096","article-title":"One hundred base pairs of 5\u2032 flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription","volume":"82","author":"Bertholet","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2010.10.021_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/315190","article-title":"Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge","volume":"181","author":"Bray","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2010.10.021_bb0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.virol.2010.10.021_bb0040","series-title":"The Mouse in Biomedical Research","author":"Buller","year":"2007"},{"key":"10.1016\/j.virol.2010.10.021_bb0045","first-page":"1","article-title":"Progressive vaccinia in a military smallpox vaccinee\u2014United States","volume":"58","author":"CDC","year":"2009","journal-title":"MMWR"},{"key":"10.1016\/j.virol.2010.10.021_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0042-6822(03)00520-8","article-title":"The genomic sequence of ectromelia virus, the causative agent of mousepox","volume":"317","author":"Chen","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.virol.2010.10.021_bb0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0042-6822(92)90445-U","article-title":"Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene","volume":"187","author":"Chen","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.virol.2010.10.021_bb0060","first-page":"431","article-title":"Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein","volume":"81","author":"Coupar","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0065","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0022-2836(89)90107-1","article-title":"Structure of vaccinia virus early promoters","volume":"210","author":"Davison","year":"1989","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virol.2010.10.021_bb0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.bcp.2006.09.014","article-title":"Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge","volume":"73","author":"De Clercq","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.virol.2010.10.021_bb0075","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.virol.2010.10.021_bb0080","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1128\/jvi.64.6.3108-3111.1990","article-title":"Transient dominant selection of recombinant vaccinia viruses","volume":"64","author":"Falkner","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0085","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/JVI.76.2.895-904.2002","article-title":"Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease","volume":"76","author":"Fernandez","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0090","doi-asserted-by":"crossref","first-page":"8672","DOI":"10.1128\/jvi.71.11.8672-8677.1997","article-title":"Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus","volume":"71","author":"Fischer","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01310729","article-title":"Association of non-viral proteins with recombinant vaccinia virus virions","volume":"94","author":"Franke","year":"1987","journal-title":"Arch. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0171-2985(00)80084-4","article-title":"Biologic functions and signaling of the interleukin-4 receptor complexes","volume":"201","author":"Gessner","year":"2000","journal-title":"Immunobiology"},{"key":"10.1016\/j.virol.2010.10.021_bb0105","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1086\/314736","article-title":"The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease","volume":"179","author":"Ghiasi","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2010.10.021_bb0110","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1128\/JVI.75.19.9029-9036.2001","article-title":"Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice","volume":"75","author":"Ghiasi","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1006\/cyto.1999.0576","article-title":"Dual effect of IL-4 on resistance to systemic gram-negative infection and production of TNF-alpha","volume":"12","author":"Giampietri","year":"2000","journal-title":"Cytokine"},{"key":"10.1016\/j.virol.2010.10.021_bb0120","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1073\/pnas.0912134107","article-title":"Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice","volume":"12","author":"Grosenbach","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2010.10.021_bb0125","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1074\/jbc.272.3.1480","article-title":"A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction","volume":"272","author":"Grunewald","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2010.10.021_bb0130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erv.09.55","article-title":"The new ACAM200 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks","volume":"8","author":"Handley","year":"2009","journal-title":"Expert Reviews"},{"key":"10.1016\/j.virol.2010.10.021_bb0135","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.4049\/jimmunol.155.3.1326","article-title":"Small amounts of exogenous IL-4 increase the severity of encephalitis induced in mice by the intranasal infection of herpes simplex virus type 1","volume":"155","author":"Ikemoto","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2010.10.021_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1095\/biolreprod58.1.152","article-title":"Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3","volume":"58","author":"Jackson","year":"1998","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.virol.2010.10.021_bb0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.75.3.1205-1210.2001","article-title":"Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox","volume":"75","author":"Jackson","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virol.2004.02.031","article-title":"Expression of rabbit IL-4 by recombinant myxoma viruses enhances virulence and overcomes genetic resistance to myxomatosis","volume":"324","author":"Kerr","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.virol.2010.10.021_bb0155","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/ar104","article-title":"Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4","volume":"2","author":"Kim","year":"2000","journal-title":"Arthritis Res."},{"key":"10.1016\/j.virol.2010.10.021_bb0160","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.172.3.921","article-title":"Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells","volume":"172","author":"Le Gros","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2010.10.021_bb0165","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.4049\/jimmunol.158.9.4478","article-title":"Transgene-induced production of IL-4 alters the development and collagen expression of T helper cell 1-type pulmonary granulomas","volume":"158","author":"Lukacs","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2010.10.021_bb0170","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/path.1700330317","article-title":"Infectious ectromelia. A hitherto undescribed virus disease of mice","volume":"33","author":"Marchal","year":"1930","journal-title":"J. Pathol. Bacteriol"},{"key":"10.1016\/j.virol.2010.10.021_bb0175","first-page":"4765","article-title":"High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12","volume":"55","author":"Meko","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2010.10.021_bb0180","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-11-255174","article-title":"Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation and tissue macrophage accumulation","author":"Milner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.virol.2010.10.021_bb0185","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/jvi.70.8.5230-5235.1996","article-title":"Interleukin-4 causes delayed virus clearance in influenza virus-infected mice","volume":"70","author":"Moran","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0190","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4049\/jimmunol.138.6.1813","article-title":"Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4)","volume":"138","author":"Mosmann","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2010.10.021_bb0195","series-title":"Current Protocols in Molecular Biology","article-title":"Expression of proteins in mammalian cells using vaccinia cirus vectors. Overview of the vaccinia virus expression system","author":"Moss","year":"1998"},{"key":"10.1016\/j.virol.2010.10.021_bb0205","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1128\/JVI.75.18.8353-8355.2001","article-title":"Creation of killer poxvirus could have been predicted","volume":"75","author":"Mullbacher","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0210","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","article-title":"Efficacy of cidofovir in a murine model of disseminated progressive vaccinia","volume":"48","author":"Neyts","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2010.10.021_bb0215","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1099\/0022-1317-50-10-936","article-title":"Possible mechanism for the enhanced lethality of an interleukin-4-expressing mousepox virus","volume":"50","author":"Norazmi","year":"2001","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.virol.2010.10.021_bb0220","series-title":"The Cytokine Handbook","article-title":"Interleukin-4","author":"Okada","year":"2003"},{"key":"10.1016\/j.virol.2010.10.021_bb0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tibtech.2004.06.008","article-title":"Design and development of oral drugs for the prophylaxis and treatment of smallpox infection","volume":"22","author":"Painter","year":"2004","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.virol.2010.10.021_bb0230","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/17460794.3.6.595","article-title":"Therapeutic and prophylactic drugs to treat orthopoxvirus infections","volume":"3","author":"Parker","year":"2008","journal-title":"Future Virology"},{"key":"10.1016\/j.virol.2010.10.021_bb0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2008.11.015","article-title":"Mousepox in the C57BL\/6 strain provides an improved model for evaluating anti-poxvirus therapies","volume":"385","author":"Parker","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.virol.2010.10.021_bb0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virol.2010.10.021_bb0245","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.iy.05.040187.002241","article-title":"B-cell stimulatory factor-1\/interleukin 4","volume":"5","author":"Paul","year":"1987","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.virol.2010.10.021_bb0250","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hygiene"},{"key":"10.1016\/j.virol.2010.10.021_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2004.12.003","article-title":"The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4","volume":"66","author":"Robbins","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virol.2010.10.021_bb0260","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1128\/jvi.70.10.7103-7107.1996","article-title":"Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo","volume":"70","author":"Sharma","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0265","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijantimicag.2003.10.010","article-title":"Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice","volume":"23","author":"Smee","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.virol.2010.10.021_bb0270","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.it.2005.04.001","article-title":"The \u201csupervirus?\u201d Lessons from IL-4-expressing poxviruses","volume":"26","author":"Stanford","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.virol.2010.10.021_bb0275","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/jvi.70.1.165-171.1996","article-title":"Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light","volume":"70","author":"Tsung","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.021_bb0280","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/587668","article-title":"Severe eczema vaccinatum in a household contact of a smallpox vaccinee","volume":"15","author":"Vora","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.virol.2010.10.021_bb0285","first-page":"41","article-title":"Kinetics of ectromelia virus (mousepox) transmission and clinical response in C57BL\/6j, BALB\/cByj and AKR\/J inbred mice","volume":"35","author":"Wallace","year":"1985","journal-title":"Lab Anim Sci."},{"key":"10.1016\/j.virol.2010.10.021_bb0290","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210006689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210006689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:11:08Z","timestamp":1758586268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682210006689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0042682210006689"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2010.10.021","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2010.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}